Alnylam Pharmaceuticals : SEC Filing - S-8

S-8

As filed with the Securities and Exchange Commission on February 13, 2020

Registration No. 333-_____

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Alnylam Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		77-0602661
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)
675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142		02142
(Address of Principal Executive Offices)		(Zip Code)

2018 Stock Incentive Plan

(Full Title of the Plan)

John M. Maraganore, Ph.D.

Chief Executive Officer

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street,

Henri A. Termeer Square

Cambridge, Massachusetts 02142

(Name and Address of Agent For Service)

[phone]

(Telephone Number, Including Area Code, of Agent For Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of 'large accelerated filer,' 'accelerated filer,' 'smaller reporting company' and 'emerging growth company' in Rule 12b2 of the Exchange Act.

Large accelerated filer		☒		Accelerated filer		☐
Non-accelerated filer		☐ (Do not check if a smaller reporting company)		Smaller reporting company		☐
		Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered		Amount to be Registered(1)		Proposed Maximum Offering Price Per Share(3)		Proposed Maximum Aggregate Offering Price(3)		Amount of Registration Fee
Common Stock, $0.01 par value per share		3,290,000 shares(2)		$120.71		$397,135,900.00		$51,548.24

(1)

In accordance with Rule 416 under the Securities Act of 1933, as amended (the 'Securities Act'), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)	Consists of 3,290,000 shares issuable under the 2018 Stock Incentive Plan, pursuant to the terms of such plan.

(3)	Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on February 6, 2020.

EXPLANATORY NOTE

This Registration Statement on Form S-8 is filed for the purposes of registering 3,290,000 additional shares of common stock, par value $0.01 per share ('Common Stock') of Alnylam Pharmaceuticals, Inc. (the 'Registrant') that may be issued pursuant to equity awards granted pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan (the '2018 Plan'). On April 25, 2019, pursuant to an Amendment to the 2018 Plan, the number of shares of Common Stock reserved and available for issuance under the 2018 Plan increased by 3,290,000. This Registration Statement registers these additional 3,290,000 shares of Common Stock. The additional shares are of the same class as other securities relating to the 2018 Plan for which the Registrant's registration statement filed on Form S-8 (Registration No. 333-226533) on August 2, 2018, is effective. The information contained in the Registrant's registration statement on Form S-8 (Registration No. 333-226533), is hereby incorporated by reference pursuant to General Instruction E, except for 'Item 8. Exhibits.'

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

Number		Description
5.1		Opinion of Goodwin Procter LLP, counsel to the Registrant
23.1		Consent of Goodwin Procter LLP (included in Exhibit 5.1)
23.2		Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
24		Power of Attorney (included on the signature page of this registration statement)
99.1		2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant's Quarterly Report on Form 10-Q filed on August 6, 2019 (File No. 001-36407) for the quarterly period ended June 30, 2019)

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 13th day of February, 2020.

ALNYLAM PHARMACEUTICALS, INC.
By:		/s/ John M. Maraganore, Ph.D.
	John M. Maraganore, Ph.D.
	Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Alnylam Pharmaceuticals, Inc., hereby severally constitute and appoint John M. Maraganore and Jeffrey V. Poulton, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Alnylam Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature		Title		Date
/s/ John M. Maraganore, Ph.D. John M. Maraganore, Ph.D.		Chief Executive Officer and Director (Principal Executive Officer)		February 13, 2020
/s/ Jeffrey V. Poulton Jeffrey V. Poulton		Chief Financial Officer (Principal Financial and Accounting Officer)		February 13, 2020
/s/ Dennis A. Ausiello, M.D. Dennis A. Ausiello, M.D.		Director		February 13, 2020
/s/ Michael W. Bonney Michael W. Bonney		Director		February 13, 2020
/s/ Marsha H. Fanucci Marsha H. Fanucci		Director		February 13, 2020
/s/ Margaret A. Hamburg, M.D. Margaret A. Hamburg, M.D.		Director		February 13, 2020
/s/ Steven M. Paul, M.D. Steven M. Paul, M.D.		Director		February 13, 2020
/s/ David E.I. Pyott David E.I. Pyott		Director		February 13, 2020
/s/ Colleen F. Reitan Colleen F. Reitan		Director		February 13, 2020
/s/ Paul R. Schimmel, Ph.D. Paul R. Schimmel, Ph.D.		Director		February 13, 2020
/s/ Amy W. Schulman Amy W. Schulman		Director		February 13, 2020
/s/ Phillip A. Sharp, Ph.D. Phillip A. Sharp, Ph.D.		Director		February 13, 2020